Updated to correct Cell Therapeutics share price
NEW YORK (
) -- Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.
surged by 52 cents, or 64.2%, to $1.33 in early trading after the company said its Maestro System continues to meet its safety goals, according to data from weight loss, hypertension and diabetes clinical studies. The 50-day average daily volume for is 856,000, according to the
slumped by 55 cents, or 15.5%, to $3 after the company said in a regulatory filing late Wednesday that is has consented to the issuance of a consent order with the Federal Deposit Insurance Corporation and the Florida Office of Financial Regulation. Atlantic Bancgroup said it entered into the consent order without admitting or denying any charges of unsafe or unsound banking practices or violations of law or regulation. The 50-day average daily volume for Atlantic Bancgroup is 4,500.
fell by 13 cents, or 9.7%, to $1.21 at the open after the company said it raised $30 million through the sale of preferred stock and warrants. The 50-day average daily volume for Cell Therapeutics is 10.61 million shares.
rose by 8 cents, or 12.9%, to 70 cents in early trading after the company announced the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer in
Breast Cancer Research and Treatment
. The results show that "Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity" in a heavily pretreated population of women diagnosed with metastatic breast cancer. The 50-day average daily volume for Bionovo is 1.28 million.
Earlier at 7:39 a.m. EST
( LAB) surged by 36% to $3.78 in Thursday's premarket session after the company said late Wednesday that it will sell its
New York Stock Exchange
designated market maker (DMM) business to
for $25 million. As a result, Labranche will no longer have a $76 million net capital requirement related to the DMM operations. Additionally, Labranche approved a redemption of all its remaining outstanding 11% senior notes due 2012, and it said it will increase its share repurchase authorization from $23.4 million remaining under the current authorization to $100 million. The three-month average daily volume for Labranche is 410,000, according to Yahoo! Finance.
should open nearly 30% lower after the company said late Wednesday that it would raise $5.1 million in a registered direct offering of units consisting of one ordinary share and a warrant to purchase one half of an ordinary share for a purchase price of $2. The 50-day average daily volume for Rosetta Genomics is 47,000, according to the
. The stock had jumped 67% to $3.09 during Wednesday's session before details of the offering were announced.
should slide during Thursday's session after the company announced several management departures late Wednesday. CEO and board member Neal Goldberg, Chief Stores Officer William Acevedo, and Chief Merchandising Officer Mary Kwan have left the company effective immediately. President Theo Killion has been appointed interim CEO and he will assume initial responsibility for all store operations. The three-month average daily volume for Zale is 1.2 million. Zale shares closed at $3.23 Wednesday before falling nearly 9% in the after-hours session.
should open higher Thursday after the company said late Wednesday that Rob Glaser has stepped down as CEO. He will remain chairman of RealNetworks, the company said. RealNetworks also announced the appointment of Robert Kimball as president and acting CEO. The management change comes one day after COO John Giamatteo said that he will resign from the company effective April 2. The 50-day average daily volume for RealNetworks is 553,000 shares. The stock finished at $3.86 Wednesday.
-- Written by Robert Holmes in Boston
Check out all of Thursday's high-volume, under-$5 stocks at the Dollar Store
Follow Robert Holmes on
and become a fan of TheStreet.com on